A study on patients’ selection for BRCA1 and BRCA2 mutations testing by different models in Libyan women with breast cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Corbex M, Bouzbid S, Boffetta P. Features of breast cancer in developing countries, examples from North Africa. Eur J Cancer. 2014;50(10):1808–8. doi: 10.1016/j.ejca.2014.03.016
   PubMed Web of Science ®Google Scholar
• Boder JM, Elmabrouk Abdalla FB, Elfageih MA, et al. Breast cancer patients in Libya: comparison with European and central African patients. Oncol Lett. 2011 Mar;2(2):323–330.
   PubMed Web of Science ®Google Scholar
• Laraqui A, Uhrhammer N, Rhaffouli HE, et al. BRCA genetic screening in Middle Eastern and North African: mutational spectrum and founder BRCA1 mutation (c.798_799delTT) in North African. Dis Markers. 2015;2015:194293. doi: 10.1155/2015/194293
   PubMed Web of Science ®Google Scholar
• Larsen MJ, Thomassen M, Gerdes AM, et al. Hereditary breast cancer: clinical, pathological and molecular characteristics. Breast Cancer. 2014 Oct 15;8:145–155. doi: 10.4137/BCBCR.S18715
   PubMedGoogle Scholar
• Mahfoudh W, Bouaouina N, Ahmed SB, et al. Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. Mol Biol Rep. 2012 Feb;39(2):1037–1046. doi: 10.1007/s11033-011-0829-8
   PubMed Web of Science ®Google Scholar
• ElBiad O, Laraqui A, El Boukhrissi F, et al. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa. BMC Cancer. 2022 Feb 25;22(1):208. doi: 10.1186/s12885-022-09181-4
   PubMed Web of Science ®Google Scholar
• Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003 May 1;72(5):1117–1130. doi: 10.1086/375033
   PubMed Web of Science ®Google Scholar
• Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004 Feb 15;22(4):735–742.
   PubMed Web of Science ®Google Scholar
• Giordano SH. A review of the diagnosis and management of male breast cancer. Oncology. 2005 Aug;10(7):471–479. doi: 10.1634/theoncologist.10-7-471
   Google Scholar
• Satagopan JM, Offit K, Foulkes W, et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):467–473. PMID: 11352856.
   PubMed Web of Science ®Google Scholar
• Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet. 1998 Mar;62(3):676–689.
   PubMed Web of Science ®Google Scholar
• Begg CB, Haile RW, Borg Å, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA. 2008;299(2):194201. doi: 10.1001/jama.2007.55-a
   Web of Science ®Google Scholar
• Armstrong J, Toscano M, Kotchko N, et al. Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: the ABOUT study. JAMA Oncol. 2015 Dec 1;1(9):1251–1260. doi: 10.1001/jamaoncol.2015.3048
   PubMed Web of Science ®Google Scholar
• Balmana J, Diez O, Rubio IT, et al. BRCA in breast cancer: ESMO clinical practice guidelines. Ann Oncol. 2011 Sep 1;22:vi31–4. doi: 10.1093/annonc/mdr373
   PubMed Web of Science ®Google Scholar
• Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002 Mar 15;20(6):1480–1490. doi: 10.1200/JCO.2002.20.6.1480
   PubMed Web of Science ®Google Scholar
• Couch FJ, Deshano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997 May 15;336(20):1409–1415. doi: 10.1056/NEJM199705153362002
   PubMed Web of Science ®Google Scholar
• Berry DA, Iversen ES Jr, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002 Jun 1;20(11):2701–2712. doi: 10.1200/JCO.2002.05.121
   PubMed Web of Science ®Google Scholar
• Evans DG, Eccles DM, Rahman N, et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 2004 Jun 1;41(6):474–480. doi: 10.1136/jmg.2003.017996
   PubMed Web of Science ®Google Scholar
• Berry DA, Parmigiani G, Sanchez J, et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. JNCI. 1997 Feb 5;89(3):227–237. doi: 10.1093/jnci/89.3.227
   PubMedGoogle Scholar
• Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008 Apr;98(8):1457–1466. doi: 10.1038/sj.bjc.6604305
   PubMed Web of Science ®Google Scholar
• Antoniou AC, Pharoah PD, McMullan G, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002 Jan;86(1):76–83. doi: 10.1038/sj.bjc.6600008
   PubMed Web of Science ®Google Scholar
• Nanda R, Schumm LP, Cummings S, et al. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19;294(15):1925–1933. doi: 10.1001/jama.294.15.1925
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003 Jun 15;21(12): 2397–2406. doi: 10.1200/JCO.2003.03.189
   PubMed Web of Science ®Google Scholar
• Abbad A, Baba H, Dehbi H, et al. Genetics of breast cancer in African populations: a literature review. Glob Health Epidemiol Genom. 2018 May 11;3:e8. doi: 10.1017/gheg.2018.8
   PubMedGoogle Scholar
• NCCN clinical practice guidelines in oncology (NCCN Guidelines) genetic/familial high-risk assessment: breast and ovarian. National Comprehensive Cancer Network; version 2.2022. [cited 2022 Mar 9]. Available from: https://www.melbournebreastcancersurgery.com.au/wp-content/themes/ypo-theme/pdf/nccn-clinical-practice-genetic.pdf
   Google Scholar
• Lim GH, Borje E, Allen JC Jr. Evaluating the performance of National Comprehensive Cancer Network (NCCN) breast and ovarian genetic/familial high risk assessment referral criteria for breast cancer women in an Asian surgical breast clinic. Gland Surg. 2017 Feb;6(1):35. doi: 10.21037/gs.2016.11.05
   PubMed Web of Science ®Google Scholar
• Varesco L, Viassolo V, Viel A, et al. Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics. Breast. 2013 Dec;22(6):1130–1135.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736–1747. doi: 10.1093/annonc/mdr304
   PubMed Web of Science ®Google Scholar
• Ehinger A, Malmström P, Bendahl PO, et al. South and South-East Swedish Breast Cancer Groups. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Acta Oncol. 2017 Jan;56(1):68–74.
   PubMed Web of Science ®Google Scholar
• ElJilani MM, Shebani AA, Bishr AM, et al. Assessment of breast cancer risk in Libyan women using the Gail model. Libyan J Med Sci. 2020 Jul 1;4(3):115. doi: 10.4103/LJMS.LJMS_26_20
   Google Scholar
• Abdulrashid K, AlHussaini N, Ahmed W, et al. Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis. BMC Cancer. 2019 Dec;19(1):1–2. doi: 10.1186/s12885-019-5463-1
   PubMedGoogle Scholar
• Riahi A, Ghourabi ME, Fourati A, et al. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families. Breast Cancer. 2017 Mar;24(2):238–244. doi: 10.1007/s12282-016-0693-4
   PubMed Web of Science ®Google Scholar
• Einbeigi Z, Bergman A, Meis-Kindblom JM, et al. Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden. Fam Cancer. 2007 Mar;6(1):35–41. doi: 10.1007/s10689-006-9101-0
   PubMed Web of Science ®Google Scholar
• Hung FH, Wang YA, Jian JW, et al. Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan. Sci Rep. 2019 Jul 15;9(1):10229. doi: 10.1038/s41598-019-46707-6
   PubMedGoogle Scholar
• Ermiah E, Abdalla F, Buhmeida A, et al. Diagnosis delay in Libyan female breast cancer. BMC Res Notes. 2012 Aug 21;5(1):452. doi: 10.1186/1756-0500-5-452
   PubMedGoogle Scholar
• Gusbi E, Elgriw N, Zalmat S, et al. Breast cancer in western part of Libya: Pattern and management (2003-2018). Libyan J Med Sci. 2020;4(2):65–71.
   Google Scholar
• Ssentongo P, Lewcun JA, Candela X, et al. Regional, racial, gender, and tumor biology disparities in breast cancer survival rates in Africa: A systematic review and meta-analysis. PLOS ONE. 2019 Nov 21;14(11):e0225039. doi: 10.1371/journal.pone.0225039
   PubMed Web of Science ®Google Scholar
• Mighri N, Mejri N, Boujemaa M, et al. Association between epidemiological and clinico-pathological features of breast cancer with prognosis, family history, Ki-67 proliferation index and survival in Tunisian breast cancer patients. PLOS ONE. 2022 Sep 12;17(9):e0269732. doi: 10.1371/journal.pone.0269732
   PubMed Web of Science ®Google Scholar
• El Fatemi H, Chahbouni S, Jayi S, et al. Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco. Diagn Pathol. 2012;7:170. doi: 10.1186/1746-1596-7-170
   PubMed Web of Science ®Google Scholar
• Al Tamimi DM, Shawarby MA, Ahmed A, et al. Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study. BMC Cancer. 2010;10. doi: 10.1186/1471-2407-10-223
   PubMed Web of Science ®Google Scholar
• Caldarella A, Buzzoni C, Crocetti E, et al. Invasive breast cancer: a significant correlation between histological types and molecular subgroups. J Cancer Res Clin Oncol. 2013;139(4):617–623.
   PubMed Web of Science ®Google Scholar
• Salhia B, Anis Ishak E, Gaber S, et al. DuQuette, James Resau, Coya Tapia, John Carpten; Abstract A103: Breast cancer molecular subtype analysis in Egypt reveals high prevalence of Luminal A: Implications for improving prognosis. Cancer Epidemiol Biomarkers Prev. 2010 Oct 1;19(10_Supplement):A103. doi: 10.1158/1055-9965.DISP-10-A103
   Google Scholar
• Fourati A, Boussen H, El May MV, et al. Descriptive analysis of molecular subtypes in Tunisian breast cancer. Asia Pac J Clin Oncol. 2014;10(2):e69–e74.
   PubMed Web of Science ®Google Scholar
• Hercules SM, Alnajar M, Chen C, et al. Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis. BMJ Open. 2022;12(5):e055735. doi: 10.1136/bmjopen-2021-055735
   PubMed Web of Science ®Google Scholar
• Cherbal F, Gaceb H, Mehemmai C, et al. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study. Breast Dis. 2015;35(2):95–102. doi: 10.3233/BD-150398 PMID: 25736840.
   PubMedGoogle Scholar
• Incorvaia L, Fanale D, Bono M, et al. BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients. Ther Adv Med Oncol. 2020 Dec 16;12:1758835920975326. doi: 10.1177/1758835920975326
   Web of Science ®Google Scholar